Welcome!

News Feed Item

New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer

DARMSTADT, Germany, March 31, 2014 /PRNewswire/ --



  • The multidisciplinary Oncology Partnership and Education Network (OPEN) aims to improve patient outcomes in oncology, with initial focus on metastatic colorectal cancer (mCRC) 
  • OPEN aims to raise public awareness and understanding of the importance of biomarker testing in mCRC 

Merck Serono, the biopharmaceutical division of Merck, today announced the formation of the global Oncology Partnership and Education Network (OPEN). This global initiative, supported by Merck Serono, brings together a multidisciplinary group of stakeholders involved with the management of cancer to help improve patient care. Focusing on metastatic colorectal cancer (mCRC) as its first priority, OPEN aims to reinforce the important role biomarker testing has in personalizing care in mCRC. The launch of OPEN coincides with Colorectal Cancer Awareness Month in many countries.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/7140053-merck-serono-metastatic-colorectal-cancer 

Based on recent scientific developments in the area of biomarkers in mCRC, OPEN's first priority will be to establish a global campaign to improve awareness and understanding with the general public, patients and healthcare professionals. OPEN, chaired by Professor Ciardiello, is supported by an international steering committee of experts in the field of oncology, including healthcare professionals, patient advocacy groups and policy representatives.

"Biomarkers enable oncologists to create personalized, clinically proven treatment plans for patients right from the start in mCRC, thereby optimizing patients' chances of extended overall survival," said Professor Fortunato Ciardiello, Seconda Università di Napoli, Naples, Italy and Chair of the OPEN Steering Committee. "OPEN aims to increase public awareness of the fact that getting a biomarker test done, ideally at the time of initial diagnosis, is vital for patients with metastatic colorectal cancer to ensure they receive the most appropriate 1st-line treatment," he concluded.

Currently, 25% of patients with colorectal cancer already have an advanced stage of the disease at diagnosis, which makes it challenging to treat successfully.[1],[2] Recent developments in the field of biomarkers now allow physicians to identify those patients who are most likely to benefit from specific treatment options, based on the genetic profile of their tumor.

"Biomarkers are reliable clinical indicators that support physicians in their treatment decisions for patients with metastatic colorectal cancer," said Dr Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety for Merck Serono. "Merck Serono is proud to be able to support OPEN in its mission to raise awareness globally of the important role biomarkers play in improving clinical outcomes for people living with mCRC."

An increased understanding of treatment options and greater involvement in decision making about their own care, together with equality of access to treatments that improve outcomes, are also core principles of the recently launched European Cancer Patient's Bill of Rights.

About Colorectal Cancer  

Colorectal cancer (CRC) is the second most common cancer worldwide, with an estimated incidence of more than 1.36 million new cases annually.[3] Approximately 694,000 deaths from CRC occur every year, accounting for 8.5% of all cancer deaths and making it the fourth most common cause of death from cancer.[3] Almost 55% of CRC cases are diagnosed in developed regions of the world, and incidence and mortality rates are substantially higher in men than in women.[3]

Note to Editors: 

Please click here to view the multimedia release which includes mCRC biomarker videos and additional information.

Additional information resources for media on mCRC are available online from: http://www.globalcancernews.com

References 

  1. Sanoff HK, et al. J Clin Oncol 2008;26(35):5721-7.
  2. Van Cutsem E, et al. Ann Oncol 2010;21(Suppl 5):v93-7.
  3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Last accessed March 2014.

About Merck Serono 

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit http://www.merckserono.com.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.

Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.

Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Contact:
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt
Germany
Hotline +49(0)6151-72-5000
http://www.merckgroup.com

Merck Serono is a division of Merck
http://www.merckserono.com
Raphaela Farrenkopf
Phone +49-6151-72-2274


Video: 
     http://www.multivu.com/mnr/7140053-merck-serono-metastatic-colorectal-cancer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, discussed the best practices that will ensure a successful smart city journey.
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT depl...
The pace of innovation, vendor lock-in, production sustainability, cost-effectiveness, and managing risk… In his session at 18th Cloud Expo, Dan Choquette, Founder of RackN, discussed how CIOs are challenged finding the balance of finding the right tools, technology and operational model that serves the business the best. He also discussed how clouds, open source software and infrastructure solutions have benefits but also drawbacks and how workload and operational portability between vendors an...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...
"Tintri was started in 2008 with the express purpose of building a storage appliance that is ideal for virtualized environments. We support a lot of different hypervisor platforms from VMware to OpenStack to Hyper-V," explained Dan Florea, Director of Product Management at Tintri, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.